A preliminary investigation on the efficacy of N-acetyl cysteine for mania or hypomania

Pedro V S Da Silva Magalhaes, Olivia Dean, Ashley I Bush, David Leon Copolov, Gin S Malhi, Kristy Kolhmann, Susan Jeavons, Ian Schapkaitz, Murray Anderson-Hunt, Michael Berk

    Research output: Contribution to journalArticleResearchpeer-review

    40 Citations (Scopus)


    Objective: Oxidative imbalance has emerged as a treatment target in bipolar disorder. As very limited data are available on the clinical use of antioxidants for mania, we report here results from a post hoc and exploratory subgroup analysis of a randomized, placebo-controlled trial of N-acetyl cysteine (NAC). Methods: This was a placebo-controlled, randomized, clinical trial assessing the effect of NAC over 24 weeks in mania or hypomania. Symptomatic and functional outcomes were collected over the study period. Results: Fifteen participants were available for this report; two participants in each group failed to complete all assessments. Within-group analyses pointed to an improvement in the NAC group on manic symptoms and worsening in the placebo group on depressive symptoms at endpoint. Conclusions: Although the sample size was small, these results indicated within-group efficacy for this glutathione precursor as compared to placebo. Future trials specifically designed to demonstrate the efficacy of NAC in mania are needed.
    Original languageEnglish
    Pages (from-to)564 - 568
    Number of pages5
    JournalAustralian & New Zealand Journal of Psychiatry
    Issue number6
    Publication statusPublished - 2013

    Cite this